Patent · US Active

KRAS G12C inhibitors and methods of using the same

US10532042B2 · kind B2 · utility

36Cited by

40References

13Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Brian Alan LANMAN · Calabasas, US
Victor J. Cee · Thousand Oaks, US
Alexander J. Pickrell · Westlake Village, US
Anthony B. Reed · Newbury Park, US
Kevin Yang · San Gabriel, US
David John Kopecky · West Hollywood, US
Hui-Ling Wang · Thousand Oaks, US
Patricia Lopez · Calabasas, US
Kate Ashton · Thousand Oaks, US
Shon Booker · Thousand Oaks, US
Christopher M. Tegley · Thousand Oaks, US

Key dates

Filing date	Dec 21, 2017
Grant date	Jan 14, 2020
Priority date	—
Expiry date	Dec 21, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.